GeneCast Biotechnology develops precision cancer diagnostics and companion diagnostics to enhance treatment outcomes for cancer patients. By utilizing genomic profiling and biomarker analysis, the company enables personalized therapy selection, improving the effectiveness of cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer treatment selection is often based on incomplete information, leading to ineffective therapies and adverse outcomes for patients. Traditional diagnostic methods may not fully capture the unique genomic and molecular characteristics of individual tumors, hindering personalized treatment strategies.
Solution
GeneCast Biotechnology develops precision cancer diagnostics that leverage genomic profiling and biomarker analysis to guide personalized therapy selection. By analyzing the unique molecular characteristics of a patient's tumor, GeneCast provides clinicians with actionable insights to optimize treatment decisions. This approach aims to improve treatment effectiveness, minimize adverse effects, and enhance overall outcomes for cancer patients. GeneCast's diagnostic solutions enable a more targeted and individualized approach to cancer care.
Target Audience
The primary target audience includes oncologists, pathologists, and pharmaceutical companies involved in cancer treatment and drug development.
Features
- Genomic profiling of tumor samples to identify actionable mutations and biomarkers
- Biomarker analysis to assess drug response and resistance mechanisms
- Personalized therapy selection based on individual tumor characteristics
- Comprehensive reports with actionable insights for clinicians